Alzheimer's disease brain-derived amyloid-ß-mediated inhibition of LTP In Vivo is prevented by immunotargeting cellular prion protein

Citation

Barry, A.E., Klyubin, I., McDonald, J.M., Mably, A.J., Farrell, M.A., Scott, M., Walsh, D.M., Rowan, M.J., Alzheimer's disease brain-derived amyloid-ß-mediated inhibition of LTP In Vivo is prevented by immunotargeting cellular prion protein, Journal of Neuroscience, 31, 20, 2011, 7259-7263

Abstract

Synthetic amyloid- protein (A ) oligomers bind with high affinity to cellular prion protein (PrPC), but the role of this interaction in mediating the disruption of synaptic plasticity by such soluble A in vitro is controversial. Here we report that intracerebroventricular injection of A -containing aqueous extracts of Alzheimer?s disease (AD) brain robustly inhibits long-term potentiation (LTP) without significantly affecting baseline excitatory synaptic transmission in the rat hippocampus in vivo. Moreover, the disruption of LTP was abrogated by immunodepletionofA . Importantly, intracerebroventricular administration of antigen-binding antibody fragment D13, directed to a putative A -binding site on PrPC, prevented the inhibition of LTP by AD brain-derived A . In contrast, R1, a Fab directed to the C terminus of PrPC, a regionnotimplicatedinbindingofA ,didnotsignificantly affect theA -mediatedinhibition ofLTP.These data support the pathophysiological significance of SDS-stable A dimer and the role of PrPC in mediating synaptic plasticity disruption by soluble A .

Description

PUBLISHED

Endorsement

Review

Supplemented By

Referenced By

Sponsor: European Commission
Grant Number: 201159

Sponsor: European Commission
Grant Number: 200611

Sponsor: Science Foundation Ireland (SFI)
Grant Number: 10/IN.1/B3001

Sponsor: Science Foundation Ireland (SFI)
Grant Number: 08/IN.1/B2033

Sponsor: Science Foundation Ireland (SFI)
Grant Number: 06/IN.1/B88

Sponsor: Health Research Board (HRB)

Author's Homepage: http://people.tcd.ie/mrowan
Type of material: Journal Article